Modality
Multispecific
MOA
WEE1i
Target
MDM2
Pathway
Wnt
Prostate Ca
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
~Apr 2019
→ ~Jul 2020
Phase 2
~Oct 2020
→ ~Jan 2022
Phase 3
Apr 2022
→ Jan 2031
Phase 3Current
NCT06012982
1,777 pts·Prostate Ca
2024-05→TBD·Active
NCT04929829
664 pts·Prostate Ca
2022-04→2031-01·Completed
2,441 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-01-124.8y awayPh3 Readout· Prostate Ca
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031
P3
Complet…
P3
Active
Catalysts
Ph3 Readout
2031-01-12 · 4.8y away
Prostate Ca
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06012982 | Phase 3 | Prostate Ca | Active | 1777 | VA |
| NCT04929829 | Phase 3 | Prostate Ca | Completed | 664 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 |